RU2018147078A - COMBINATION OF ANTIVIRAL AGENTS, SET AND METHOD OF TREATMENT ON ITS BASIS - Google Patents

COMBINATION OF ANTIVIRAL AGENTS, SET AND METHOD OF TREATMENT ON ITS BASIS Download PDF

Info

Publication number
RU2018147078A
RU2018147078A RU2018147078A RU2018147078A RU2018147078A RU 2018147078 A RU2018147078 A RU 2018147078A RU 2018147078 A RU2018147078 A RU 2018147078A RU 2018147078 A RU2018147078 A RU 2018147078A RU 2018147078 A RU2018147078 A RU 2018147078A
Authority
RU
Russia
Prior art keywords
combination according
agent
combination
mammal
mass ratio
Prior art date
Application number
RU2018147078A
Other languages
Russian (ru)
Other versions
RU2726210C2 (en
RU2018147078A3 (en
Inventor
Роберт Шалвович Бибилашвили
Александр Васильевич Кононов
Алексей Викторович Кравченко
Анастасия Львовна Хандажинская
Алина Руслановна Симонян
Original Assignee
Общество С Ограниченной Ответственностью "Пролонгированные Лекарства"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Пролонгированные Лекарства" filed Critical Общество С Ограниченной Ответственностью "Пролонгированные Лекарства"
Priority to RU2018147078A priority Critical patent/RU2726210C2/en
Priority to PCT/RU2019/001031 priority patent/WO2020139163A2/en
Priority to KR1020217023854A priority patent/KR20210119408A/en
Priority to BR112021017961A priority patent/BR112021017961A2/en
Priority to CN201980093074.5A priority patent/CN113473994A/en
Publication of RU2018147078A3 publication Critical patent/RU2018147078A3/ru
Publication of RU2018147078A publication Critical patent/RU2018147078A/en
Application granted granted Critical
Publication of RU2726210C2 publication Critical patent/RU2726210C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Claims (12)

1. Комбинация для лечения ВИЧ-инфекции, содержащая (i) аммониевую соль 5'-аминокарбонилфосфонат-3'-азидо-3'-дезокситимидина и (ii) аналог цитидина, выбранный из эмтрицитабина и ламивудина, при массовом соотношении агента (i) к агенту (ii) от 250:1 до 1:250.1. The combination for the treatment of HIV infection containing (i) ammonium salt of 5'-aminocarbonylphosphonate-3'-azido-3'-deoxythymidine and (ii) an analog of cytidine selected from emtricitabine and lamivudine, in a mass ratio of agent (i) to agent (ii) from 250: 1 to 1: 250. 2. Комбинация по п. 1, характеризующаяся тем, что дополнительно содержит фармацевтически приемлемый носитель.2. The combination according to claim 1, characterized in that it further comprises a pharmaceutically acceptable carrier. 3. Комбинация по п. 1 или 2, характеризующаяся тем, что массовое соотношение агента (i) к агенту (ii) составляет от 1:50 до 50:1.3. The combination according to claim 1 or 2, characterized in that the mass ratio of agent (i) to agent (ii) is from 1:50 to 50: 1. 4. Комбинация по п. 1 или 2, характеризующаяся тем, что массовое соотношение агента (i) к агенту (ii) составляет от 1:10 до 10:1.4. The combination according to claim 1 or 2, characterized in that the mass ratio of agent (i) to agent (ii) is from 1:10 to 10: 1. 5. Комбинация по п. 1 или 2, характеризующаяся тем, что предназначена для перорального введения.5. The combination according to claim 1 or 2, characterized in that it is intended for oral administration. 6. Комбинация по п. 5, характеризующаяся тем, что выполнена в виде таблетки, в том числе для размещения в блистерной упаковке.6. The combination according to claim 5, characterized in that it is made in the form of a tablet, including for placement in a blister pack. 7. Комбинация по п. 5, характеризующееся тем, что выполнена в виде капсулы, в том числе для размещения в блистерной упаковке.7. The combination according to claim 5, characterized in that it is made in the form of a capsule, including for placement in a blister pack. 8. Комбинация по п. 1 или 2, характеризующаяся тем, что предназначена для одновременного введения агентов (i) и (ii).8. The combination according to claim 1 or 2, characterized in that it is intended for the simultaneous administration of agents (i) and (ii). 9. Комбинация по п. 1 или 2, характеризующаяся тем, что предназначена для последовательного введения агентов (i) и (ii).9. The combination according to claim 1 or 2, characterized in that it is intended for sequential administration of agents (i) and (ii). 10. Набор для лечения ВИЧ-инфекции, включающий комбинацию по любому из пп. 1-9 и инструкцию по применению указанной комбинации.10. A kit for treating HIV infection, comprising a combination according to any one of paragraphs. 1-9 and instructions for use of the specified combination. 11. Способ лечения ВИЧ-инфекции у млекопитающего, характеризующийся тем, что включает введение млекопитающему, нуждающемуся в этом, терапевтически эффективного количества комбинации по любому из пп. 1-9.11. A method of treating HIV infection in a mammal, characterized in that it comprises administering to the mammal in need of a therapeutically effective amount of a combination according to any one of claims. 1-9. 12. Способ по п. 11, характеризующийся тем, что млекопитающим является человек.12. The method according to p. 11, characterized in that the mammal is a human.
RU2018147078A 2018-12-27 2018-12-27 Combination of antiviral agents, kit and method of treatment based thereon RU2726210C2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
RU2018147078A RU2726210C2 (en) 2018-12-27 2018-12-27 Combination of antiviral agents, kit and method of treatment based thereon
PCT/RU2019/001031 WO2020139163A2 (en) 2018-12-27 2019-12-26 Combination of antiviral agents, kit and treatment method based on same
KR1020217023854A KR20210119408A (en) 2018-12-27 2019-12-26 antiviral compound
BR112021017961A BR112021017961A2 (en) 2018-12-27 2019-12-26 Combination of antiviral agents, kit and treatment method based on them
CN201980093074.5A CN113473994A (en) 2018-12-27 2019-12-26 Combination of antiviral agents, kits and methods of treatment based thereon

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2018147078A RU2726210C2 (en) 2018-12-27 2018-12-27 Combination of antiviral agents, kit and method of treatment based thereon

Publications (3)

Publication Number Publication Date
RU2018147078A3 RU2018147078A3 (en) 2020-06-29
RU2018147078A true RU2018147078A (en) 2020-06-29
RU2726210C2 RU2726210C2 (en) 2020-07-09

Family

ID=71130174

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018147078A RU2726210C2 (en) 2018-12-27 2018-12-27 Combination of antiviral agents, kit and method of treatment based thereon

Country Status (5)

Country Link
KR (1) KR20210119408A (en)
CN (1) CN113473994A (en)
BR (1) BR112021017961A2 (en)
RU (1) RU2726210C2 (en)
WO (1) WO2020139163A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023018714A2 (en) * 2021-03-15 2023-10-24 Transposon Therapeutics Inc USE OF A LINE-1 INHIBITOR TO TREAT OR PREVENT ATAXIA-TELANGIECTASIA, AGE-RELATED MACULAR DEGENERATION, SYSTEMIC LUPUS ERYTHEMATOSUS, IFN-ASSOCIATED AUTOIMMUNE DISEASE, FANCONI ANEMIA, IDIOPATHIC PULMONARY FIBROSIS, OR CARDIOVASCULAR DISEASE AND KIT COMPRISING A LINE INHIBITOR -1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2308136T3 (en) * 2003-01-14 2008-12-01 Gilead Sciences, Inc. COMPOSITIONS AND PROCEDURES FOR ANTIVIRAL POLYTHERAPY.
RU2331420C2 (en) * 2005-12-08 2008-08-20 Роберт Шалвович Бибилашвили Antiviral agent (versions) and treatment method based on it
RU2441016C1 (en) * 2010-05-28 2012-01-27 Закрытое акционерное общество "Производственно-коммерческая Ассоциация АЗТ" 5'-aminocarbonylphophonate 3'-azido-3'-deoxythymidine salts being selective inhibitors of human immunodeficiency virus hiv-1
RU2446169C2 (en) * 2010-05-28 2012-03-27 Закрытое акционерное общество "Производственно-коммерческая Ассоциация АЗТ" Method of producing 5'-aminocarbonylphosphonates of nucleosides and method of producing acyl chloride of trimethylsilyl ether of ethoxycarbonylphosphonic acid
WO2012164241A1 (en) * 2011-05-30 2012-12-06 Cipla Limited Pharmaceutical antiretroviral composition
KR101976231B1 (en) * 2011-10-14 2019-05-07 자크리토에 악치오네르노에 오브쉐스토보 ＂프로이즈보드스트벤노-콤머체스카야 아쏘치아치야 아즈트＂ Salts of carbamoyl phosphonic acid esters which act as selective inhibitors of human immunodeficiency virus hiv-1 production
MX364901B (en) * 2012-10-23 2019-05-10 Cipla Ltd Pharmaceutical antiretroviral composition.

Also Published As

Publication number Publication date
RU2726210C2 (en) 2020-07-09
WO2020139163A2 (en) 2020-07-02
BR112021017961A2 (en) 2021-12-28
KR20210119408A (en) 2021-10-05
RU2018147078A3 (en) 2020-06-29
WO2020139163A3 (en) 2020-08-27
CN113473994A (en) 2021-10-01

Similar Documents

Publication Publication Date Title
CA2682254A1 (en) 1,3-oxathiolane nucleoside analogues
JP2016508134A5 (en)
RU2007132181A (en) ANTI-CANCER MEDICINE CONTAINING α, α, α-TRIFTORTIMIDINE AND A THIMIDINFOSPHORILYLASE INHIBITOR
DK1173178T3 (en) Composition comprising apomorphine and sildenafil and its use in the treatment of erectile dysfunction
RU94013464A (en) NUCLEOSIDE ANALOGUES 1,3-OXATIOLANE, METHOD OF OBTAINING, PHARMACEUTICAL COMPOSITION, METHOD OF TREATING VIRAL INFECTION
RU2013148779A (en) TREATMENT OF HEPATITIS VIRUS INFECTION IN SEPARATELY OR IN COMBINATION WITH DELTA HEPATITIS VIRUS AND LIVER-LIVING DISEASES OF THE LIVER
RU2012101881A (en) Azapeptides Derivatives
RU2005114018A (en) EPOTHYLON D + FLUORORACIL / HEMCITABINE
RU2014139825A (en) Derivatives of Ingenols for the Reactivation of the Latent HIV Virus
RU2006131553A (en) COMBINATION (A) OF DNA TOPOISOMERASE INHIBITOR AND (B) IAP INHIBITOR
PH12019501016A1 (en) Treatment of cns diseases with sgc stimulators
RU2010151660A (en) METHODS FOR TREATING MULTIPLE MYELOMA
RU2004135563A (en) MEDICINE FOR TREATING AN INCREASED ACTIVITY OF THE BLADDER
JP2005517040A5 (en)
JP2023009229A5 (en)
RU2007132971A (en) METHODS AND MATERIALS WITH TRANS-CLOMIPHENES FOR TREATMENT OF MEN'S INFERTILITY
RU2018147078A (en) COMBINATION OF ANTIVIRAL AGENTS, SET AND METHOD OF TREATMENT ON ITS BASIS
FI3493812T3 (en) Combinations of imetelstat and venetoclax for the treatment of acute myeloid leukaemia
RU2002122084A (en) COMBINATION OF MEDICINES, INCLUDING MIRTAZAPINE, FOR THE TREATMENT OF DEPRESSION AND RELATED DISORDERS
WO2005023270A3 (en) Compositions and methods for use of antiviral drugs in the treatment of retroviral diseases resistant to nucleoside reverse transcriptase inhibitors
RU2005131578A (en) APLIDINE FOR TREATMENT OF MULTIPLE MYELOMA
DE69328667T2 (en) COMPOSITION CONTAINING FLAVOPEREIRINE AND THEIR USE IN THE TREATMENT AGAINST HIV VIRUSES
RU2015111491A (en) COMBINATION OF THE MACROCYCLIC HCV PROTEASE INHIBITOR, HCV NON-NUCLEOSIDE INHIBITOR AND RITONAVIR
RU2013129824A (en) NEW TREATMENT OF HEPATITIS C VIRUS INFECTION
RU2005138167A (en) ANTIVIRAL AGENT (OPTIONS) AND METHOD OF TREATMENT ON ITS BASIS